

-6-

Claim 28 -- Amended by this Amendment

h2
20 --28. A nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising a variable heavy chain region amino acid sequence corresponding to amino acid 1 through amino acid 122 of SEQ [IN] ID NO: 12.--

Claim 29 -- Unchanged by this Amendment

--29. Hybridoma 5G1.1 having ATCC designation HB-11625.--

Claim 30 -- Unchanged by this Amendment

--30. An antibody produced by the hybridoma of claim 29.--

Claim 31 -- Added by this Amendment

h3
23 --31. An antibody comprising at least one antibody-antigen binding site, said antibody exhibiting specific binding to human complement component C5, said specific binding being targeted to the alpha chain of human complement component C5, wherein:

(A) the antibody inhibits (i) C5b-9-mediated hemolysis and (ii) C5a generation in a fluid comprising human serum; and

(B) the antibody does not specifically bind to the human complement activation product free C5a.--

REMARKS

Claim 21 has been amended to more generally describe the therapeutic agent called for by that claim. Support for this amendment can be found at page 31, lines 21-34, of applicants' specification.

Claim 28 has been amended to correct a typographical error.

Claim 31 has been added to further define applicants' invention. Support for this claim can be found in applicants' specification at, for example, page 12, lines 13-16 & 27-30, and in Example 12.

201

1K

-7-

The Commissioner is hereby authorized to charge any fees required
for the filing of this amendment to Deposit Account No. 11-1158.

Respectfully submitted,

Date:

12/13/99

Maurice Klee

Maurice M. Klee, Ph.D.
Reg. No. 30,399
Attorney for Applicant
1951 Burr Street
Fairfield, CT 06430
(203) 255-1400

K